On April 3, 2017, Susan Keown, of Fred Hutch News, published an article on updated data from the research team behind the pivotal trial of avelumab in metastatic, treatment-resistant MCC. The data presented from their study shows the drug has gone on to break even its own impressive record in these patients.
Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Click here to view the article.Click to Download PDF
The authoritative source on Merkel cell carcinoma.
September 13, 2019